Breast Cancer Clinical Trials in Philadelphia, Pennsylvania

35 studies are recruiting for breast cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients

   This is a pilot trial to assess how measures of inflammation are correlated with Social Determinants of Health (SDoH) in breast cancer patients. Expected duration of subject participation is one single time point. The patients will fill out questionnaires and provide a plasma sample.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07478016 on ClinicalTrials.gov

2. FES BPET-DBT in Newly Diagnosed Breast Cancer

   Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 20 evaluable subjects will p…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT05659797 on ClinicalTrials.gov

3. Safe and Explainable AI

   While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical know…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT06694181 on ClinicalTrials.gov

4. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

5. CTNNA1 Familial Expansion Study

   The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT05126290 on ClinicalTrials.gov

6. [18F] F-GLN by PET/CT in Breast Cancer

   Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.0 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging co…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT03863457 on ClinicalTrials.gov

7. Prospective Breast Cancer Biospecimen Collection

   Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, m…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT04074720 on ClinicalTrials.gov

8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

9. Surviving Daily Life

   The primary goal of this project is to evaluate the feasibility of a 14-day mobile daily diary study among racially diverse breast cancer survivors. Further, the investigators will examine the validity and reliability of the daily stress and daily cognitive performance measures among breast cancer …

   Stage

   Not phased

   Ages

   40 and older

   Site

   Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07054723 on ClinicalTrials.gov

10. Role of the Immune Environment in Response to Therapy in Breast Cancer

    This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Abramson Cancer Center, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT05396612 on ClinicalTrials.gov